Transcript:
Arun B. Jesudian, MD: When we talk about refractory patients, we’re all transplant professionals so I think we have to discuss liver transplantation as a treatment for very severe HE [hepatic encephalopathy]. Can you give us an overview of: is it effective, does it cure this condition, does it come back?
Steven L. Flamm, MD: Well, certainly when patients develop hepatic encephalopathy, that is considered a decompensation, even if they don’t yet have ascites or variceal bleeding or other complications, and it’s been shown in multiple studies that within a few years these patients have a high mortality. So they should, in my opinion, be referred for liver transplantation evaluation when they get encephalopathy. And this one’s also a little tricky because in between episodes of encephalopathy the patients are normal, or they appear normal. So you might think when they’re better that, well, it’s not so bad right now. But usually it’s a harbinger of bad things to come. So they should be evaluated for transplant. Now certainly if they continue to do poorly from an encephalopathy standpoint or develop other complications of end-stage liver disease, or a poor synthetic function for liver testing, those are reasons you would proceed with liver transplant. And when you do liver transplant, one of the dogmas always has been that the encephalopathy has no long-lasting consequences, that it’s reversible. It was a toxic metabolic event only, without structural changes in the brain, and therefore, when the new liver is put in and a toxic metabolic insult is removed, that you don’t have any consequences.
There have been some studies more recently that have called that into question. For instance, some patients after liver transplant who have had encephalopathy before transplant have learning issues. They don’t learn as well when given computerized testing or pen and paper tests, pencil and paper tests. So there may be some consequences in a fraction of patients that have encephalopathy, after liver transplant. I’m not aware of any major cognition issues, but Elliot may have something different to comment on this, but [no] major issues after transplant. But certainly it’s a transplant indication and certainly you should proceed with transplantation if you really can’t get the patient’s liver status under control. Do you have any comments on post-transplant changes?
Elliot B. Tapper, MD: I agree with you, and that’s what you experience in your own clinical practice, in our own clinical practice. But I think the data suggest that over time repeated episodes of encephalopathy are neurotoxic, and we have the basic science to back that up. But when you transplant somebody, you are creating such a dramatic improvement in their life, more often than not, that those changes are really minor in the grand scheme of things. And I think, although there’s caveats and asterisks, it is a cure for hepatic encephalopathy.
Arun B. Jesudian, MD: And a common question that we get, just to put to rest, if you have encephalopathy do you get any added priority for transplantation on the waiting list?
Elliot B. Tapper, MD: We prioritize patients based on a relatively objective algorithm called the MELD [model for end-stage liver disease] score, which is based exclusively on renal function, sodium, the INR [international normalized ratio], and bilirubin. And unfortunately, the suffering of some patients who don’t have high MELD scores continues in the MELD-based calculation. It just does not give you any priority, unfortunately.
Steven L. Flamm, MD: Yes, the MELD score, the model for end-stage liver disease, is solely based on objective criteria—[laboratory test results], as Elliot said. There’s no accommodation for encephalopathy. And some patients have a low MELD score and yet have terrible recurrent encephalopathy. And sadly for them, they will not get a liver through the regular channels. What does that mean? If a program does living liver donation, liver transplantation, which we do at Northwestern [University Feinberg School of Medicine], they can get a liver because it’s not based on a MELD score allocation system. But if they’re in the regular allocation system, [there’s] no accommodation for it. It’s very sad. These patients really are not dealt with well with the current system.
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
A Novel Approach to Chronic GVHD With Axatilimab: Dr Daniel Wolff
October 18th 2024The latest therapy approved to treat chronic graft-versus-host disease (GVHD) has a new target different than the other approved therapies. Daniel Wolff, MD, also discusses future research on axatilimab to treat chronic GVHD earlier.
Read More
From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care
May 30th 2024In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Listen
Data Show Undocumented Latinx People Face Disproportionate Burden of Long COVID
October 17th 2024New findings show that undocumented Latinx immigrants, who make up 7% of the US population, face significant challenges in accessing health care due to uninsurance, limited access to care, language barriers, and fears surrounding their immigration status.
Read More